Atlas Trials

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Clinical trial NCT04466150 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04466150
Sponsor
University of California, San Francisco
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Relapsing Multiple SclerosisClinically Isolated Syndrome
Start date
2020-08-30
Primary completion
2026-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.